Intraperitoneal administration of recombinant human growth hormone in children with end-stage renal disease

Gipson, Debbie S.; Kausz, Annamaria T.; Striegel, Jane E.; Melvin, Tyrone R.; Astrom, Linda J.; Watkins, S. L.
January 2001
Pediatric Nephrology;2001, Vol. 16 Issue 1, p29
Academic Journal
Recombinant human growth hormone (GH) therapy has been shown to be effective in the treatment of growth failure related to growth hormone resistance among children with chronic renal failure. The traditional route of administration is subcutaneous injection. This study was designed to evaluate the effectiveness and tolerability of intraperitoneal (IP) administration of GH in prepubertal peritoneal dialysis patients. Nine subjects were enrolled. Eight completed 24 months of therapy with GH. Baseline height standard deviation scores (SDS) and growth velocity for the prior year were used for comparison. Peak serum GH was achieved 4 h after administration and serum half-life was 4.6 h. Mean height SDS was −3.1 at baseline, −2.5 at 1 year, and −2.3 at 2 years (NS) of GH therapy. Mean height velocity increased from a baseline of 4.6 cm/yr to 8.5 cm/yr in year 1 (P<0.05) and 6.1 cm/yr in year 2 (NS) of IP GH therapy. Peritonitis infection rates were not increased from overall center rates. This research suggests that the intraperitoneal route of administration of GH can be utilized in the treatment of short stature among children requiring maintenance peritoneal dialysis therapy.


Related Articles

  • 386. Treatment for more than 1 year resulted in no demonstrable benefit of growth hormone in children with renal failure. Vimalachandra, D.; Craig, J.C.; Cowell, C.T. // Kidney;May/Jun2002, Vol. 11 Issue 3, p128 

    Provides information on a study which examined growth hormone treatment in children with chronic renal failure. Methodology; Results; Conclusion.

  • Start GH at Young Age, and Early in Course of CRF.  // Kidney;May/Jun99, Vol. 8 Issue 3, p128 

    Discusses the abstract of a study entitled `Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure,' by D. Haffner, E. Wuhl, F. Schaeffer and others, published in the 1998 'Journal of the American Society of Nephrology.'

  • Serum leptin and IGF-I during growth hormone treatment in chronic renal failure. Patel, Leena; Webb, Nicholas A.; Bradbury, Mark G.; Zaman, Nasra; Smith, Patricia; Lewis, Malcolm A.; Postlethwaite, Robert J.; Price, David A.; Clayton, Peter E. // Pediatric Nephrology;Aug2002, Vol. 17 Issue 8, p643 

    Serum leptin decreases during growth hormone (hGH) treatment and pre-treatment values have been suggested as a predictor of the response to hGH in GH deficiency (GHD) but not in non-GHD syndromes. To investigate whether this holds true in children with chronic renal failure (CRF), we evaluated...

  • Reversible diabetes mellitus during growth hormone therapy in chronic renal failure. Filler, Guido; Franke, Doris; Amendt, Peter; Ehrich, Jochen H. H. // Pediatric Nephrology;1998, Vol. 12 Issue 5, p405 

    A 12-year-old girl with short stature due to idiopathic Fanconi syndrome and chronic renal failure was treated with recombinant human growth hormone (rhGH). There was no family history of diabetes mellitus and the glucose tolerance before treatment was normal. Intravenous glucose tolerance tests...

  • Somatomedin and growth retardation in children with chronic renal insufficiency. Lewy, John E.; VanWyk, Judson J. // Kidney International;Oct1978, Vol. 14 Issue 4, p361 

    The somatomedins are a family of growth hormone-dependent insulin-like peptides which have been postulated to mediate the actions of pituitary growth hormone on skeletal tissue. The somatomedin peptides are part of a larger family of growth factors. Somatomedin has been measured by bioassays, by...

  • The impact of recombinant human growth hormone treatment on final adult height. Fine, R. K.; Sullivan, E. K.; Tejani, A. // Pediatric Nephrology;Jul2000, Vol. 14 Issue 7, p679 

    There are limited data addressing the issue of final adult height following treatment with recombinant human growth hormone (rhGH). Utilizing the chronological age of 18 years as the arbitrary age of final adult height for children with chronic renal insufficiency, all patients enrolled in the...

  • Growth in children with established renal failure—a Registry analysis (Chapter 14). Lewis, Malcolm; Shaw, Joanne; Reid, Chris; Evans, Jonathan; Webb, Nicholas; Verrier-Jones, Kate // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_7, pvii176 

    Short stature is a major problem in paediatric ERF patients with 29% of transplant patients and 41% of dialysis patients below the second percentile for height. Only 6.5% of transplant patients and 15.5% of dialysis patients are receiving rhGH. There is no significant difference in the height...

  • Growth hormone receptor abundance in tibial growth plates of uremic rats: GH/IGF-I treatment. Edmondson, Stephanie R.; Baker, Naomi L.; Oh, Jun; Kovacs, Gabor; Werther, George A.; Mehls, Otto // Kidney International;Jul2000, Vol. 58 Issue 1, p62 

    Growth hormone receptor abundance in tibial growth plates of uremic rats: GH/IGF-I treatment. Background. Children with chronic renal failure (CRF) exhibit growth retardation and a disturbed growth hormone/insulin-like growth factor-I (GH/IGF-I) axis. Treatment of children with CRF with GH or...

  • somatropin.  // Royal Society of Medicine: Medicines;2002, p505 

    The article presents information on the biosynthetic human growth hormone somatropin. The name is used to distinguish it from the natural human product somatotropin that it replaced in Great Britain. Somatropin is used to treat short stature (dwarfism) when the condition is due to growth hormone...

  • Challenges for Nephrology Nurses in the Management of Children with Chronic Kidney Disease. Miller, Deborah; Macdonald, Dina; Kolnacki, Ken; Simek, Teresa // Nephrology Nursing Journal;May/Jun2004, Vol. 31 Issue 3, p295 

    Presents a series of questions for nephrology nurses, on the management of children with chronic kidney disease (CKD). Primary causes for CKD in children; Formula recommended for estimating creatinine clearance in children; Basis of growth hormone dose calculations and dose increases.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics